AHA 2024 - Marc Bonaca presents the results of a sub-study from the CLEAR Outcomes trial on the effects of bempedoic acid on adverse limb event in statin-intolerant patients with symptomatic peripheral artery disease (PAD).
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
AHA 2024 - Marc Bonaca presents the results of a sub-study from the CLEAR Outcomes trial on the effects of bempedoic acid on adverse limb event in statin-intolerant patients with symptomatic peripheral artery disease (PAD).
This video was recorded during the AHA Scientific Sessions 2024 in Chicago, IL, US.
Marc Bonaca, MD is a cardiologist and vascular medicine specialist and is the executive director of CPC Clinical Research and CPC Community Health at the University of Colorado, Boulder, CO, US.
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Release date: 21 November 2024
AHA 2024 - Marc Bonaca presents the results of a sub-study from the CLEAR Outcomes trial on the effects of bempedoic acid on adverse limb event in statin-intolerant patients with symptomatic peripheral artery disease (PAD).
This video was recorded during the AHA Scientific Sessions 2024 in Chicago, IL, US.
Marc Bonaca, MD is a cardiologist and vascular medicine specialist and is the executive director of CPC Clinical Research and CPC Community Health at the University of Colorado, Boulder, CO, US.
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Release date: 21 November 2024
Stay current with the best on medical education
